Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Blue Mesa Health

Webcast: Securing a future for telehealth with immersive market research insights

Research Partnership investigate the current landscape, the challenges to adoption and the future for telehealth.

Research Partnership

- PMLiVE

Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’

Results announced at the American Heart Association Scientific Sessions this week suggest the drug dramatically cuts LDL cholesterol levels

Woman on mobile phone

How femtech is changing the future of women’s health

The femtech industry has the potential to be the next stage of evolution in the open access movement. Taking on the role of a public library, which allows a wider...

Thrive Agency

- PMLiVE

UK’s MHRA approves first oral antiviral against COVID-19

Merck's Lagevrio has been approved for people with mild to moderate COVID-19 and at least one risk factor for developing severe illness

- PMLiVE

Merck receives first breast cancer approval in Europe for Keytruda

Merck’s anti-PD-1 therapy, Keytruda, is approved in the Europe Union for certain patients with triple-negative breast cancer plus chemotherapy

Unlocking the Potential of Electronic Medical Records Using Artificial Intelligence

Dr. Javier Mendoza, Gastroenterologist and Digital Health Expert, explores digital health in medicine and clinical research, natural language processing, the ethics surrounding AI, and his experience as a medical doctor...

Impetus Digital

- PMLiVE

Merck and Ridgeback’s oral antiviral halves COVID-19 risk of hospitalisation or death

The phase 3 study shows the risk was halved compared to placebo for patients with mild or moderate COVID-19

- PMLiVE

Merck to acquire Acceleron in a deal worth around $11.5bn

The acquisition of the biopharmaceutical company will complement and strengthen Merck’s cardiovascular pipeline

- PMLiVE

Mysterious big pharma company eyes US biotech Acceleron

Speculation is running high that a major pharma company will make a move on Massachusetts-based pulmonary and haematology biotech Acceleron this week

- PMLiVE

Lynparza significantly delays disease progression as first-line treatment in prostate cancer

New data show AstraZeneca and Merck‘s PARP inhibitor, Lynparza, delayed disease progression as a first-line treatment in advanced prostate cancer

- PMLiVE

FDA approves Seagen/Genmab’s antibody-drug conjugate Tivdak for women with advanced cervical cancer

The drug has been granted accelerated approval, and the companies have also released positive data on first-line treatment

Digitalizing Muskuloskeletal Care to Improve Patient Outcomes and Reduce Cost

Lydia Zeller, CEO at Kiio, explores digital therapeutics, healthcare innovation, and Kiio’s innovative and personalized solutions for musculoskeletal (MSK) pain. She also shares her key leadership lessons and predictions for...

Impetus Digital

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links